Del 256 i serien Handbook of Experimental Pharmacology

Bile Acids and Their Receptors

Häftad, Engelska, 2020

1 579 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

This book focusses on the latest results related to the field of bile acids as signaling molecules and describes how these receptors have become a major pharmacological target.

Produktinformation

Utgivningsdatum2020-09-19
Mått155 x 235 x 21 mm
Vikt587 g
FormatHäftad
SpråkEngelska
SerieHandbook of Experimental Pharmacology
Antal sidor378
FörlagSpringer Nature Switzerland AG
ISBN9783030220075

Tillhör följande kategorier

Preface.- Part 1. Bile acids as signaling molecules and their receptors.- 1. A short history of bile acid pharmacology.- 2. Bile acids activated receptors: a review of GPBAR1 (TGR5) and other G-protein-coupled receptors.- 3. Bile acid activated receptors: a review of FXR and other Nuclear receptors.- 4. The intestinal enterokine fibroblast growth factor 15/19 in bile acid metabolism.- 5. Signaling from intestine to the host. How bile acids regulate intestinal and liver immunity.- Part 2. General pharmacology of bile acid activated receptors and their ligands.- 6. Modeling of bile acid activated receptors as a tool for pharmacological development.- 7. Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists and antagonists.- 8. Non steroidal FXR ligands: current status and clinical applications.- 9. Intestinal selective FXR agonists and their potential in treating liver and metabolic diseases.- Part 3. Bile acids and their derivatives as drugs.- 10. UDCA, Nor-UDCA and T-UDCA: a review of their mechanisms of action and clinical applications.- 11. Chenodeoxycholic acid: an update on its therapeutic appplications and safety profile.- 12. Obeticholic acid: a review of its mechanisms of action and clinical applications.- Part 4. Bile acid activated receptors as therapeutic targets.- 13. Targeting FXR in cholestasis.- 14. FXR agonists for the treatment of NASH and other metabolic disorders.- 15. Targeting bile acids activated receptors in bariatric surgery.